Australia's veterinary medicines regulator has suspended the usage of the antibiotic florfenicol in Tasmania's salmon farming industry due to concerns over its effect on marine ecosystems. The decision follows the detection of traces of the drug in wild fish located 10 kilometers away from the farms, which raised alarms about the potential risks florfenicol could pose not only to surrounding marine species but also to public health and the environment at large. Green advocacy groups, such as the Bob Brown Foundation, have heavily criticized the industrial fish farming practices that led to this situation, depicting it as a significant failure of environmental responsibility by the companies involved.

Previously, the Australian Pesticides and Veterinary Medicines Authority (APVMA) had issued an emergency permit for the use of florfenicol to treat outbreaks of the bacterial disease piscirickettsiosis, a move initially deemed necessary due to a mass mortality incident that affected over 1 million salmon. This outbreak, characterized by unprecedented levels of fish deaths in February 2025, prompted the industry to rely on this antibiotic treatment as a last resort to mitigate losses. However, the alarming discovery of florfenicol traces in the wild prompted the APVMA to reassess the overall health implications and ecological risks associated with its continued use in salmon farming.

The suspension comes as a crucial step in protecting both the marine environment and public health, highlighting broader concerns regarding antibiotic use in aquaculture and its potential consequences on biodiversity. With pressures mounting on the fish farming industry to adopt more sustainable practices, this decision emphasizes the importance of regulatory oversight in ensuring responsible environmental management. Stakeholders and industry leaders will need to find alternative solutions to manage diseases in aquaculture without compromising the ecological integrity of surrounding habitats.